These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 33346109)

  • 1. Risk of venous thromboembolism in rheumatoid arthritis.
    Ketfi C; Boutigny A; Mohamedi N; Bouajil S; Magnan B; Amah G; Dillinger JG
    Joint Bone Spine; 2021 May; 88(3):105122. PubMed ID: 33346109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting.
    Liang H; Danwada R; Guo D; Curtis JR; Kilpatrick RD; Hendrickson B; Islam SS
    RMD Open; 2019; 5(2):e001013. PubMed ID: 31673413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review.
    Mori S; Ogata F; Tsunoda R
    Clin Rheumatol; 2021 Nov; 40(11):4457-4471. PubMed ID: 34554329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs.
    Kim SC; Solomon DH; Liu J; Franklin JM; Glynn RJ; Schneeweiss S
    Am J Med; 2015 May; 128(5):539.e7-17. PubMed ID: 25534420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk-Enriched Rheumatoid Arthritis Patients.
    Charles-Schoeman C; Fleischmann R; Mysler E; Greenwald M; Ytterberg SR; Koch GG; Bhatt DL; Wang C; Mikuls TR; Chen AS; Connell CA; Woolcott JC; Menon S; Chen Y; Lee K; Szekanecz Z
    Arthritis Rheumatol; 2024 Aug; 76(8):1218-1229. PubMed ID: 38481002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
    Mease P; Charles-Schoeman C; Cohen S; Fallon L; Woolcott J; Yun H; Kremer J; Greenberg J; Malley W; Onofrei A; Kanik KS; Graham D; Wang C; Connell C; Valdez H; Hauben M; Hung E; Madsen A; Jones TV; Curtis JR
    Ann Rheum Dis; 2020 Nov; 79(11):1400-1413. PubMed ID: 32759265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study.
    Ogdie A; Kay McGill N; Shin DB; Takeshita J; Jon Love T; Noe MH; Chiesa Fuxench ZC; Choi HK; Mehta NN; Gelfand JM
    Eur Heart J; 2018 Oct; 39(39):3608-3614. PubMed ID: 28444172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of venous thromboembolism in patients with rheumatoid arthritis.
    Kim SC; Schneeweiss S; Liu J; Solomon DH
    Arthritis Care Res (Hoboken); 2013 Oct; 65(10):1600-7. PubMed ID: 23666917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for venous thromboembolism and atherosclerotic cardiovascular disease: do they differ in patients with rheumatoid arthritis?
    Ozen G; Pedro S; Schumacher R; Simon T; Michaud K
    RMD Open; 2021 Jun; 7(2):. PubMed ID: 34193517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization.
    Holmqvist ME; Neovius M; Eriksson J; Mantel Ä; Wållberg-Jonsson S; Jacobsson LT; Askling J
    JAMA; 2012 Oct; 308(13):1350-6. PubMed ID: 23032551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis.
    Molander V; Bower H; Frisell T; Delcoigne B; Di Giuseppe D; Askling J;
    Ann Rheum Dis; 2023 Feb; 82(2):189-197. PubMed ID: 36150749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study.
    Desai RJ; Pawar A; Weinblatt ME; Kim SC
    Arthritis Rheumatol; 2019 Jun; 71(6):892-900. PubMed ID: 30552833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of venous thromboembolism associated with methotrexate versus hydroxychloroquine for rheumatoid arthritis: A propensity score-matched cohort study.
    He M; Pawar A; Desai RJ; Glynn RJ; Lee H; Weinblatt ME; Solomon DH; Kim SC
    Semin Arthritis Rheum; 2021 Dec; 51(6):1242-1250. PubMed ID: 34757241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venous thromboembolism and risk of cancer in patients with rheumatoid arthritis.
    Pedersen AB; Vandenbroucke J; Horváth-Puhó E; Sørensen HT
    J Thromb Haemost; 2017 Dec; 15(12):2325-2332. PubMed ID: 28913891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden.
    Molander V; Bower H; Frisell T; Askling J
    Ann Rheum Dis; 2021 Feb; 80(2):169-175. PubMed ID: 33032998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors.
    Weitz JI; Szekanecz Z; Charles-Schoeman C; Vranic I; Sahin B; Paciga SA; Wang Z; Hyde C; Martin DA
    RMD Open; 2022 Nov; 8(2):. PubMed ID: 36323490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of introducing biologics to patients with rheumatoid arthritis on the risk of venous thromboembolism: a nationwide cohort study.
    Chen CP; Kung PT; Chou WY; Tsai WC
    Sci Rep; 2021 Aug; 11(1):17009. PubMed ID: 34426637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease activity as a risk factor for venous thromboembolism in rheumatoid arthritis analysed using time-averaged DAS28CRP: a nested case-control study.
    Yoshimura M; Fujieda Y; Sugawara M; Kono M; Kato M; Yokota I; Amengual O; Ito YM; Atsumi T
    Rheumatol Int; 2022 Nov; 42(11):1939-1946. PubMed ID: 35384451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of venous thromboembolism after total knee arthroplasty in patients with rheumatoid arthritis.
    Izumi M; Migita K; Nakamura M; Jiuchi Y; Sakai T; Yamaguchi T; Asahara T; Nishino Y; Bito S; Miyata S; Kumagai K; Osaki M; Mawatari M; Motokawa S
    J Rheumatol; 2015 Jun; 42(6):928-34. PubMed ID: 25877506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommendations for assessing the risk of cardiovascular disease and venous thromboembolism before the initiation of targeted therapies for chronic inflammatory rheumatic diseases.
    Avouac J; Fogel O; Hecquet S; Daien C; Elalamy I; Picard F; Prati C; Salmon JH; Truchetet ME; Sellam J; Molto A;
    Joint Bone Spine; 2023 Sep; 90(5):105592. PubMed ID: 37201575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.